Elisabeth de Darkó
Geen lopende functies
Loopbaan van Elisabeth de Darkó
Eerdere bekende functies van Elisabeth de Darkó
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Yamanouchi Nordic | Hoofd Techniek/Wetenschap/O&O | - | - |
| Algemeen Adviseur | - | - | |
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Algemeen Directeur | 01-04-2006 | - |
Statistieken
Internationaal
| Denemarken | 3 |
Operationeel
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| General Counsel | 1 |
Sectoraal
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
| Yamanouchi Nordic |
- Beurs
- Insiders
- Elisabeth de Darkó
- Ervaring
